In a decisive briefing on March 5, a high-ranking official from the Food and Drug Administration (FDA) challenged recent claims made by uniQure regarding its Huntington’s disease program. The dispute centers on the interpretation of clinical data and the regulatory requirements for the gene therapy candidate AMT-130.
Conflict over trial methodology The regulatory body maintains that current findings are insufficient due to the absence of an internal randomized control arm. The FDA has mandated a sham-controlled study to mitigate the placebo effect, citing the heterogeneous nature of Huntington’s disease and the subjective nature of its clinical endpoints.
In contrast, the developers argue that performing invasive procedures—involving skull incisions—on patients who do not receive the actual treatment is ethically problematic and imposes an undue burden. They have instead relied on external natural history databases as a primary comparative framework.
Dispute over regulatory commitments The FDA official denied that the agency ever committed, in writing or otherwise, to accepting external controls as the definitive basis for approval. Furthermore, the official pointed to discrepancies in the data, noting that the therapy showed no significant advantage over sham subjects within a 12-month window in randomized settings, despite appearing successful when compared to historical patient records.
Regulatory climate and oversight This confrontation emerges amidst a period of intensifying scrutiny over biological drug policies. A significant decrease in independent advisory committee meetings since mid-2025 and shifting leadership dynamics within the biologics sector have sparked a broader debate regarding the balance between rigorous scientific standards and the urgent need for rare disease treatments.